UB251
ProductCeftazidime for Injection
Strength0.5g; 1.0g; 1.5g; 2.0g; 2.5g
IndicationsSepsis; Lower respiratory tract infection; Intra-abdominal infection; Biliary tract infection; Complicated urinary tract infection; Skin and soft tissue infection; Opportunistic infection; Nosocomial infection; Central nervous system infection
TherapeuticsInfectious Diseases
GMPCN - NMPA; JP - PMDA
RegistrationJapan
ModalitiesSmall Molecule
Exclusive Summary
- - Originator patents expired long ago (launched in the 1980s), with a fully generic global market today.
- - Covers severe Gram-negative infections including Pseudomonas, addressing large needs such as 49M sepsis cases and 150M UTIs annually.
- - Listed on the WHO Essential Medicines List (AWaRe Watch); featured in major guidelines as an empiric/targeted anti-pseudomonal option.
- - PMDA GMP certification and Japanese registration signal high quality and facilitate reliance/accelerated registrations and hospital access in multiple regions.
- - Broad strengths (0.5/1.0/1.5/2.0/2.5g) reduce wastage and enable precise dosing, improving tender competitiveness and total treatment cost control.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →